Tegafur, Gimeracil and Oteracil Potassium is named as a drug or biological intervention in 4 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1), Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1) and LaNova Medicines Zhejiang Co., Ltd. (1). Registered phases: Phase 2, Phase 4 and Phase 2/3. Conditions studied include Gastric Cancer; Resectable Gastric/Gastroesophageal Junction Adenocarcinoma; Malignant Neoplasms of Digestive Organs.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07643623 | Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma (ClinicalTrials.gov ↗) Resectable Gastric/Gastroesophageal Junction Adenocarcinoma |
Phase 2/3 | Recruiting |
| NCT05934331 | A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study (ClinicalTrials.gov ↗) Malignant Neoplasms of Digestive Organs |
Phase 2 | Recruiting |
| NCT05498766 | Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients (ClinicalTrials.gov ↗) Gastric Cancer |
Phase 4 | Not yet open |
| NCT06487702 | A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Esophageal Squamous Cell Carcinoma |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Gastric Cancer | 1 |
| Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | 1 |
| Malignant Neoplasms of Digestive Organs | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 1 |
| LaNova Medicines Zhejiang Co., Ltd. | 1 |
| Rui-hua Xu, MD, PhD | 1 |
| Register | Tegafur, Gimeracil and Oteracil Potassium trials |
|---|---|
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tegafur, Gimeracil and Oteracil Potassium works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tegafur, Gimeracil and Oteracil Potassium (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.